Certara
AI-powered biosimulation and regulatory science platform for accelerating drug development and FDA submissions.
What it does
Certara is a biosimulation and regulatory science company that uses AI and pharmacokinetic/pharmacodynamic (PK/PD) modeling to accelerate drug development decisions and support FDA regulatory submissions. Its platform includes Phoenix for PK/PD modeling and simulation, Simcyp for physiologically-based pharmacokinetic (PBPK) simulation, and D360 for integrated drug discovery data management. AI capabilities include machine learning models that predict drug behavior in the body from molecular structure, AI-powered regulatory intelligence that identifies the optimal clinical trial design and dosing strategy based on modeling, automated population PK analysis, and natural language processing tools that help scientists navigate the regulatory submission landscape. Certara is used by major pharmaceutical companies, biotech firms, and regulatory agencies to reduce the number of clinical trials needed and increase submission approval rates.
Why AI-ENHANCED
Certara is an established biosimulation platform that has integrated AI molecular property prediction, ML population analysis, and AI regulatory intelligence into a mature pharmacokinetic modeling and regulatory science product.
Best for
Large pharmaceutical companies and biotech firms use Certara for biosimulation-based drug development - AI and PK/PD modeling reducing clinical trial requirements, informing dosing decisions, and supporting FDA submissions with quantitative evidence.
Limitations
Certara's biosimulation and PK/PD modeling platforms require specialized pharmacokineticists and clinical pharmacologists to build and interpret models — the AI augments domain experts rather than enabling non-specialists to perform biosimulation.
Certara's platform is built for pharmaceutical drug development — medical device companies, diagnostics, and non-pharma life sciences have limited applicable use cases.
Certara's platform is priced for pharmaceutical industry clients with large R&D budgets — small biotechs and academic researchers often access Certara through academic licensing or specific project consulting rather than enterprise subscriptions.
Alternatives by segment
| If you need… | Consider instead |
|---|---|
| Clinical trial data management | Medidata |
| AI drug discovery platform | BenevolentAI |
| Regulatory submission management | Veeva |
Certara enterprise contracts not published. Platform subscriptions and consulting services priced separately. Pharmaceutical enterprise contracts run millions annually. Academic and small biotech licensing available.
